Dr. Dominik Schaffner

Longevity medicine right now is on the verge of exploding because there's so much evidence that we now have.

It goes way beyond peptides.

It goes metabolic optimization, NADs, stem cells, exosomes.

There's a lot of different pathways in longevity medicine.

peptides deserve to be taken seriously and there's a lot of research that needs to succeed for them to be mass market products um currently the most most peptides and research uh phase only right but surely there's a lot of potential and there can be a lot of benefits if used in the right frameworks and if researched properly and applied on an evidence base

Look, that's exactly, you know, one of the concerns, right?

In, you know, in science, right?

One year or two years is three years worth of data and nothing, right?

Like 10 years, 15 years upwards, that's data, right?

So we don't have that data right now on peptides, right?

There's some promising research at the moment that shows incredible results, right?

But there's no long-term data.

And I don't think it's going to be like smoking.

But we have to be very careful step by step and assess this in accordance with our frameworks and the TGA and the best evidence we have.

No, you aren't, Kyle.

Look, we would have to assess this based on the merits of your case, right?

So a full comprehensive longevity assessment, right?

That then also may entail peptides, right?

But in saying so, right, there's much more to it, right?

You have to assess medical history, biomarker testing, full longevity panels, right?